Eversept Partners LP Trims Stock Position in Zenas BioPharma, Inc. $ZBIO

Eversept Partners LP lessened its position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 23.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 121,016 shares of the company’s stock after selling 37,726 shares during the quarter. Eversept Partners LP owned about 0.23% of Zenas BioPharma worth $4,394,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter worth $30,000. GF Fund Management CO. LTD. acquired a new position in shares of Zenas BioPharma during the fourth quarter worth $38,000. BNP Paribas Financial Markets grew its stake in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares in the last quarter.

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Fairmount Funds Management Llc bought 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average cost of $20.00 per share, with a total value of $3,000,000.00. Following the completion of the purchase, the director owned 2,359,025 shares of the company’s stock, valued at approximately $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 273,768 shares of company stock valued at $5,150,198 over the last ninety days. Insiders own 22.00% of the company’s stock.

Analyst Upgrades and Downgrades

ZBIO has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Morgan Stanley raised their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.29.

Zenas BioPharma Trading Up 2.1%

Shares of NASDAQ:ZBIO opened at $18.58 on Thursday. The company has a 50 day moving average of $19.25 and a 200-day moving average of $24.12. The firm has a market cap of $1.17 billion, a P/E ratio of -2.19 and a beta of -0.71. Zenas BioPharma, Inc. has a twelve month low of $8.91 and a twelve month high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter last year, the business earned ($0.80) earnings per share. As a group, analysts anticipate that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current fiscal year.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.